GS 441524 – CAS 1191237-69-0

100600

GS 441524 is provided by Santiago Lab (Prague, Czech Republic)

Purity (LC-MS)

99%

Package contents

GS 441524

This compound is for research use only. We do not sell to patients.
SizeAvailabilityPriceQuantity
10 mg

In stock

100
50 mg

In stock

180
100 mg

In stock

300
500 mg

In stock

400
1 g

In stock

600
SKU: N/A Category:

Characterisation

CAS: 1191237-69-0

IUPAC Name:(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile

Other names: Nukleosid of remdesivir; GS 441524

Molecular weight: 291.27 g/mol

Molecular formula: C12H13N5O4

Description

Nukleosid is essential bulding block to synthesis of remdesivir triphosphate (1355149-45-9) and remdesivir (1809249-37-3). Nukleosid derivate is used in treatment of Feline infectious peritonitis (FIP). This fatal disease affects cats and is caused by virus from group of coronavirus. Remdesivir is nukleosid prodrug that metabolizes into GS-441524 which is phosphorylated to remdesivir triphosphate. This phosphorus analog is mainly active compound in treatment of Ebola and COVID-19.

Chemicals are distributed worldwide

Buy GS 441524 now, get your order in 48 hours
  • Shipping through FedEx in EU in 48 hours
  • When you buy whole AVIROMIX you get shipping in EU for free
  • All compounds are safely and rigorously packed
  • For the shipment outside the EU contact us

Payment

  • We are sending the invoice the same day as the shipment
  • We are able to modify the invoice for the academic institution, so the order can be paid from grants
References

1. Butler, T.; Cho, A.; Kim, C. U.; Saunders, O. L.; Zhang, L. Preparation of 1'-substituted carba-nucleoside analogs as antiviral agents. 2009-US41447, 2009132135, 20090422., 2009.
2. Cho, A.; Saunders, O. L.; Butler, T.; Zhang, L.; Xu, J.; Vela, J. E.; Feng, J. Y.; Ray, A. S.; Kim, C. U., Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg. Med. Chem. Lett. 2012, 22 (8), 2705-2707.
3. Mackman, R. L.; Parrish, J. P.; Ray, A. S.; Theodore, D. A. Preparation of nucleosides and nucleotides for treating paramyxoviridae virus infections. 2011-US45102, 2012012776, 20110722., 2012.
4. Warren, T. K.; Jordan, R.; Lo, M. K.; Ray, A. S.; Mackman, R. L.; Soloveva, V.; Siegel, D.; Perron, M.; Bannister, R.; Hui, H. C.; Larson, N.; Strickley, R.; Wells, J.; Stuthman, K. S.; Van Tongeren, S. A.; Garza, N. L.; Donnelly, G.; Shurtleff, A. C.; Retterer, C. J.; Gharaibeh, D.; Zamani, R.; Kenny, T.; Eaton, B. P.; Grimes, E.; Welch, L. S.; Gomba, L.; Wilhelmsen, C. L.; Nichols, D. K.; Nuss, J. E.; Nagle, E. R.; Kugelman, J. R.; Palacios, G.; Doerffler, E.; Neville, S.; Carra, E.; Clarke, M. O.; Zhang, L.; Lew, W.; Ross, B.; Wang, Q.; Chun, K.; Wolfe, L.; Babusis, D.; Park, Y.; Stray, K. M.; Trancheva, I.; Feng, J. Y.; Barauskas, O.; Xu, Y.; Wong, P.; Braun, M. R.; Flint, M.; McMullan, L. K.; Chen, S.-S.; Fearns, R.; Swaminathan, S.; Mayers, D. L.; Spiropoulou, C. F.; Lee, W. A.; Nichol, S. T.; Cihlar, T.; Bavari, S., Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature (London, United Kingdom) 2016, 531 (7594), 381-385.
5. Clarke, M. O. N. H.; Jordan, R.; Mackman, R. L.; Ray, A. S.; Siegel, D. Preparation of amino acid-containing nucleosides for treating flaviviridae virus infections. 2017-US28243, 2017184668, 20170419., 2017.
6. Siegel, D.; Hui, H. C.; Doerffler, E.; Clarke, M. O.; Chun, K.; Zhang, L.; Neville, S.; Carra, E.; Lew, W.; Ross, B.; Wang, Q.; Wolfe, L.; Jordan, R.; Soloveva, V.; Knox, J.; Perry, J.; Perron, M.; Stray, K. M.; Barauskas, O.; Feng, J. Y.; Xu, Y.; Lee, G.; Rheingold, A. L.; Ray, A. S.; Bannister, R.; Strickley, R.; Swaminathan, S.; Lee, W. A.; Bavari, S.; Cihlar, T.; Lo, M. K.; Warren, T. K.; Mackman, R. L., Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J. Med. Chem. 2017, 60 (5), 1648-1661.
7. Brown, D. G.; Bostrom, J., Where Do Recent Small Molecule Clinical Development Candidates Come From? J. Med. Chem. 2018, 61 (21), 9442-9468.
8. Beigelman, L.; Deval, J.; Prhavc, M. Preparation of substituted nucleosides, nucleotides and analogs thereof as antiviral agents. 2018-IB57188, 2019053696, 20180918., 2019.
9. Peng, G.; Liu, Z. Cat coronavirus inhibitor composition composed of GC376 and GS-441524 and its application in preparing medicine for treating feline infectious peritonitis. 2019-10554607, 110215456, 20190625., 2019.
10. Pedersen, N. C.; Perron, M.; Bannasch, M.; Montgomery, E.; Murakami, E.; Liepnieks, M.; Liu, H., Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. Journal of feline medicine and surgery 2019, 21 (4), 271-281.
11. Heiser, K.; McLean, P. F.; Davis, C. T.; Fogelson, B.; Gordon, H. B.; Jacobson, P.; Hurst, B.; Miller, B.; Alfa, R. W.; Earnshaw, B. A.; Victors, M. L.; Chong, Y. T.; Haque, I. S.; Low, A. S.; Gibson, C. C., Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2. bioRxiv 2020, 1-15.
12. Huynh, T.; Wang, H.; Luan, B., In silico exploration of molecular mechanism and potency ranking of clinically oriented drugs for inhibiting SARS-CoV-2's main protease. ChemRxiv 2020, 1-22.

Related products: